Systemic administration of imiquimod as an adjuvant improves immunogenicity of a tumor-lysate vaccine inducing the rejection of a highly aggressive T-cell lymphoma

von Sciullo, Paula Di
Veröffentlicht in: Clinical immunology (Orlando, Fla.) (2019)